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Medicinal Cannabis Users Downplaying and Shifting Stigma: 
Articulations of the ‘natural’, of what is/is not a ‘drug’ and oppositions 
with ‘chemical’ substances. 
Abstract 
Whilst sympathy exists among the general public for chronically ill and/or 
disabled people who use cannabis medicinally, cannabis remains a prohibited 
substance in the UK. How do medicinal cannabis users negotiate this 
potential stigma when talking about their use of this substance? I reflect on 
the spoken discourses of 10 medicinal cannabis users (from a sample of 32), 
obtained by way of qualitative interviews, adopting a critical discourse analysis 
approach to the data. Specifically, I focus on their articulations around three 
related themes: cannabis as a ‘natural’ substance, discursive oppositions 
between cannabis and other substances and articulations about what is/is not 
a ‘drug’. I examine how participants articulated these themes in ways that 
attempted to negotiate the potential for stigma that talking about their 
substance use involved. I found they used rhetorical strategies that downplay 
their own deviance, attempt to shift the application of stigma to users of other 
substances or both. I argue that the more powerful the discursive resources 
that are articulated, the less rhetorical work an individual has to do to 
negotiate positive moral standing in an encounter. I also consider to what 
degree these articulations involved constructions emphasising individual self-
control. I argue that in asserting that cannabis is a ‘natural’ substance (and 
therefore is less inherently risky to use than manufactured substances) the 
participants do emphasise their individual self-control. 
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A significant body of research exists regarding how illicit drug users attempt to 
maintain a positive perception of the self when discussing their substance use 
and that of others (see Peretti-Watel, 2003; Hellum, 2005; Rødner, 2005; 
Omel’chenko, 2006; Radcliffe and Stevens, 2008; Hathaway et al., 2011; 
Sandberg, 2012; Mostaghim and Hathaway, 2013). However, less research 
exists that considers this with regard to medicinal cannabis users (see Bottorff 
et al., 2013; Pedersen, 2014) and even less considers this and the 
discursive/rhetorical techniques involved in doing so (Author, 2018). As well 
as being methodologically significant (see Author, 2018) this is important 
because medicinal cannabis users occupy a distinct position in the respect 
that they have come to use an illicit substance out of necessity to deal with the 
symptoms of a chronic illness or an impairment, yet still have to deal with the 
stigma associated with the use of that substance and its’ illegality.  
 
In order to understand how medicinal cannabis users attempt to maintain a 
positive perception of the self when discussing their use of this substance, 
and the discursive/rhetorical techniques they use when doing so, I reflect 
upon the discourses of 10 medicinal cannabis users (from a set of interviews I 
conducted with 32 participants). I concentrate on three related themes - 
articulations involving ideas about cannabis being ‘natural’, discursive 
constructions of what is/is not a ‘drug’ and discursive oppositions between 
 3 
cannabis and ‘chemical’ substances. Whatever themes stigma management 
elicits, there are two basic strategies, which I call downplaying and shifting. 
Individuals can attempt to downplay their own deviance, they can attempt to 
shift the application of stigma onto others, or they can combine the two.  
 
After reflecting upon instances of participants’ articulations, I argue that the 
more powerful the discursive resources that are articulated, the less rhetorical 
work an individual has to do to negotiate positive moral standing in an 
encounter. I also argue that in asserting that cannabis is a ‘natural’ substance 
(and therefore is less inherently risky to use than manufactured substances) 
the participants emphasise their individual self-control. 
 
Background 
Cannabis tincture was a popular medicinal substance, for addressing pain, 
between 1840 and 1900 (Grinspoon, 1994). Over the span of the twentieth 
century, cannabis increasingly became understood as a recreational ‘drug’, 
with connotations of deviance, as opposed to a substance with medical 
potential. However, since the early 1970s in the U.S. (Dunn and Davis, 1974) 
and later in the UK (Author, 2003; Ware et al., 2005) and other countries, a 
growing number of people have reported using cannabis for a range of 
symptomatic benefits. Typically these are individuals with a range of chronic 
illnesses (for example multiple sclerosis or arthritis) or impairments (for 
example spinal cord injury). Subject to the illness or impairment in question, 
they report a range of benefits from using cannabis (Author, 2003; Ware et al., 
2005; Sexton, et al. 2016). 
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Despite what tend to be labelled as ‘anecdotal’ claims for cannabis’ medical 
efficacy, as well as clinical evidence (see Zimmer and Morgan, 1995; Dansak, 
1997; Hollister, 2001; Musty and Rossi, 2001; Leung, 2011; Kickman and 
King, 2014), cannabis remains a controlled class B substance under the 1971 
Misuse of Drugs Act, in the United Kingdom. From November 1st 2018, expert 
doctors have been able to prescribe cannabis-based medicines in the UK 
(GOV.UK, 2018), not cannabis per se. Many medicinal users argue that 
cannabis is the only substance that provides them with symptomatic relief and 
a reasonable quality of life (Author, 2003), but in using it they live with the 
possibility of criminal prosecution. Whilst it has been argued that cannabis has 
undergone a degree of ‘normalization’ among a section of typically, though not 
exclusively, younger people in the UK (Parker et al., 1998; Parker, 2005), the 
use of any illegal substance for others, and the potential for stigmatisation and 
criminalisation, remains a very sensitive issue. Of the 10 participants I discuss 
in this article, eight had used cannabis prior to using it medicinally and two 
had not. For those who had used cannabis in a recreational fashion, this 
tended to be when they were significantly younger, with a gap between this 
and their later medicinal use. 
 
Context 
Medicinal cannabis use must be located within the context of increasing levels 
of scepticism towards contemporary health division and its’ institutions around 
many issues (see Clobert et al., 2015; Biss, 2014; Zheng, 2015 from 
thousands of papers) and an increasing affinity for ‘natural’ products in 
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everyday life (see Moscato and Machin, 2018; Nissen, 2015; Rozin et al., 
2004). As Porter (1997) noted, from the inter-war years until about 1970, 
patients, broadly speaking, regarded the medical profession as benign and 
the populace generally wanted more of the profession. Yet, by the 1970s 
there was a growing part of the population who were no longer convinced that 
scientific-medicine was the best, or only, approach for dealing with illness 
(1997). It is perhaps the case that fractions of the population, living in an 
increasingly media-saturated society, were becoming sceptical about bio-
medical solutions and were unlikely to remain as enthralled with scientific-
medicine as they once were. 
 
Illich (1995) comments on the change in attitude to scientific-medicine in the 
U.S. in the 1970s, but also touches on something broader: 
 
              “A generation ago, children in kindergarten had painted the 
doctor as a white-coated father-figure. Today, however, they will 
just as ready paint him as a man from Mars or a Frankenstein 
[...] a new mood of wariness among patients has caused 
medical and pharmaceutical companies to triple expenses for 
public relations […]. Americans have come to accept the idea 
that they are threatened by pesticides, additives, and 
mycotoxins and other health risks” (Illich 1995: 225-226). 
 
Illich ties the criticism of science and scientific-medicine to concerns around 
the environment, with science seen as ‘meddling with nature’ and as being a 
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danger, rather than a benefit, to humanity. The dystopian discourse that he 
refers to is also interesting as it is a prominent feature of the way in which 
other contemporary concerns, for example those around genetically modified 
foods and cloning, are often articulated in public discourse. Such concerns 
around scientific-medicine, cloning and genetically modified foods draw on 
common discursive resources that may be located within the increasingly 
fraught nature-society public debate (Beck 1992; Murphy, 2018; Nerlich et al. 
1999; Robbins et al., 2014; Sutton 1999). 
 
Such narratives frequently involve the discursive opposition of science and the 
’chemical’, to that which is articulated as being ‘natural’. Coward argues that 
‘nature’ has powerful associations with notions of virtue, morality, cleanliness, 
purity, renewal, vigour and goodness (Coward 1989; cited in Lypton 1995) and 
the opposition between this and the representations of ‘Frankensteinian’ 
scientific-medicine with its iatrogenic effects (Illich 1995) is obvious and 
understandably appealing. 
 
In the changing relationship between society and nature, nature is 
increasingly seen not just as something to be preserved and appreciated, but 
also as the provider of alternatives to the inherent manufactured risks of ‘non-
natural’ products. Such articulations are seen in many public discourses, such 
as food and medicine (Moscato and Machin, 2018; Nissen, 2015; Rozin et al., 
2004). As I will discuss, they can also been found within the discourses of 
medicinal cannabis users. 
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Talking about drug use: discourse, identity, normalization and stigma 
Rhetorical work in which individuals manage the perception of the self, the 
substance in question and their use of it, is commonly found in interviews with 
drug users (see Peretti-Watel, 2003; Hellum, 2005; Rødner, 2005; 
Omel’chenko, 2006; Radcliffe and Stevens, 2008; Hathaway et al., 2011; 
Sandberg, 2012; Mostaghim and Hathaway, 2013; Pedersen, 2014). Such 
research is mindful of Goffman’s (1968) advice that those who could be seen 
as ‘discreditable’ people can pass as ‘normal’ providing that they can manage 
information about the source of potential ‘shame’. How drug users present 
themselves in interviews is very much about managing that information and 
attempting to influence how they are perceived. Methodologically, it is 
important to see these identities as contextual to the interview and co-
constructed by the interviewer, shaped by the interviewer and interviewees’ 
understandings of the interview and aims of the research (see Author, 2018). 
The strategies that I call downplaying (where an individual plays down the 
stigma associated with their behaviour) and shifting (shifting the application of 
stigma onto others), or both, are found across this literature. In a discussion of 
how heroin users negotiate the ‘junkie’ identity in interviews, Radcliffe and 
Stevens (2008) note how their participants excluded themselves from this 
category, but also acknowledged its’ validity regarding ‘others’. Similarly, 
Rødner discussed how those she described as “socially integrated drug 
users” (2005: 333) contrasted their drug use with those that they constructed 
as ‘drug abusers’. Peretti-Watel (2003) built on Sykes and Matza’s (1957) 
neutralization theory, which discussed the verbal techniques that juvenile 
offenders used to justify or excuse their behaviour. Peretti-Watel (2003) found 
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that French cannabis users he interviewed engaged in risk denial by 
contrasting their cannabis use with ‘hard’ drugs, comparing cannabis to 
alcohol and emphasizing the risks of the latter. Mostaghim and Hathaway 
(2013) noted how Canadian undergraduates exhibited a more nuanced and 
fluid understanding of being a ‘user’ or ‘non-user’ of cannabis, dependent on 
the context of the social situation. 
Hammersley et al. (2001) presented three aspects of the process by way of 
which cannabis users negotiated identities in social encounters. Signification 
involved considering the meanings of the drug in question, as understood by 
the social actors involved. I would suggest that this also involves how each 
actor imagines that the other understands the drug in question and, perhaps, 
the universe of meanings around ‘drugs’ more broadly (which tend to be 
negative). They discussed negotiation in relation to how the cannabis user 
negotiated their self-presentation, subject to audience and the context of the 
social situation. For me (see Author, 2018), in interviews, both participant and 
interviewer are negotiating identities, though the participant usually has much 
more work to do to negotiate stigma. Finally, Hammersley et al. (2001) 
discussed categorisation. Categorisation is what was being negotiated, how 
one actor was understood by another, in terms of extant categories, for 
example, Rødner’s (2005) ‘drug user’ or ‘drug abuser’. I am also interested in 
the kinds of identities that are ‘conjured’ by my participants, ‘others’ that are 
used in comparison to make themselves look better or onto whom blame can 
be shifted.  
Sandberg (2012) identified ‘normalization’, subcultural and risk denial 
discourses in his interviews with Norwegian cannabis users. He concluded 
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that all of these could be seen as responses to stigmatization, challenging 
ideas around the assumed normalization of cannabis in Western societies 
minimising the amount of stigma that users might feel they have to manage. 
This idea is supported by the very existence of so much rhetorical work being 
exhibited by participants in such research. If they did not feel the potential for 
stigmatisation, why would they negotiate how they portray themselves and 
their cannabis use so much in their interviews? Hathaway et al. (2011: 451) 
discussed this in relation to Goffman’s distinction between normalization and 
normification, arguing that:  
 
“ … stigma is internalized by users which results in the active 
reinforcement and performance of established cultural requirements 
emphasizing self-control.” 
 
I examine the three themes articulated by my users and see whether they use 
these to emphasize self-control or whether there is more to it than that. 
Regarding the normalization thesis literature, much has changed since 
Measham et al. (1994), Parker et al. (1995) and Parker et al. (1998), some 20 
years ago. Since then, critics have made their points, e.g. Shiner and 
Newburn (1997) and many others since, and the literature has proliferated. 
The reader may wish to read the special issue of the journal Drugs, 
Education, Prevention and Policy from 2016, for a perspective (nearly) 20 
years later.  
However, my paper focuses on medicinal cannabis use more than drug 
normalization per se, or as it is increasingly referred to in the literature 
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Cannabis for Therapeutic Purposes (CTP). Within the changing normalization 
literature, the concept of ‘differentiated normalization’ (MacDonald and Marsh, 
2002; Shildrick, 2002) has some relevance here, not with regard to youth 
culture and drug use, but to think about medicinal cannabis use, in particular, 
and whether normalization has occurred around it. It is a complicated picture 
though, which I can only give a flavour of due to space. Less research into the 
management of stigma relating to medicinal cannabis users, than recreational 
drug users, exists. Pedersen (2014) interviewed Norwegian cannabis users 
who identified as medicinal users with self-diagnosed ADHD. He discussed 
the need among his participants to engage in rhetorical work, as all of them 
had previously been recreational cannabis users. The symbolic boundary 
work attempted to establish and maintain ‘medical user’ identities in 
opposition to ‘recreational use’ others and their own ‘recreational use’ pasts. 
Acevedo (2007) found that UK media coverage in 2004 defined British 
cannabis users (including medicinal users) as otherwise law-abiding, but that 
cannabis use after the reclassification to class B was described in much of the 
media in far less positive ways. Even after the legalization of cannabis for 
medicinal use in Canada, in 2001, Bottorff et al. (2013) found that the 
ambiguity between cannabis being a legal ‘medicine’ and an illegal ‘drug’ 
meant that stigma remained an issue for Canadian medicinal users over ten 
years later. Sznitman and Lewis (2015) found that 69% of stories in the three 
biggest selling Israeli newspapers, about medicinal cannabis, framed 
cannabis as a medicine. Yet even 31% of stories, that were about medicinal 
use, still framed cannabis as an illicit ‘drug’. So the discourse of ‘cannabis as 
medicine’ found significant resistance. To complicate matters even more, 
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Asbridge et al. (2016) discussed a usually overlooked issue within cannabis 
normalization, the practice of smoking it with tobacco. If normalization is 
occurring around cannabis, recreationally, medicinally or both, Asbridge et al. 
argue that de-normalization is occurring around tobacco. This raises the very 
curious question as to whether, at some point in the future, cannabis users 
(medicinal or otherwise) could potentially be stigmatised more for their use of 
tobacco (if they smoke cannabis) than for the cannabis they mix it with?   
As well as existing literature on how substance users rhetorically construct 
identities, manage stigma and on medicinal cannabis use and normalization, 
there is also work discussing the broader discourses existing within society 
that construct psychoactive substances as objects of knowledge and practice. 
Space limits discussion of this work, which has a long history - see Lindesmith 
(1940) and Christie and Bruun (1969) for example. However, Tupper (2012) 
discussed three contemporary meanings of the word ‘drug’ and showed how 
these inform public policy and discourses. Importantly, for my work, public 
discourses of course includes the discourses of drug users themselves. 
Tupper discussed the three categories of psychoactive substances as: ‘drugs’ 
(illegal psychoactives associated with negative connotations such as addiction 
and criminality), ‘non-drugs’ (legal psychoactives that tend to be seen as less 
dangerous, e.g. alcohol, or associated with little danger, e.g. coffee) and 
‘medicines’ (psychoactive substances permitted for restricted use under the 
direction of medical staff). Interestingly, one may ask the question as to 
whether changes in the legal, social and political context of cannabis use in 
recent years in many countries around the world has meant that cannabis now 
occupies all three of Tupper’s (2012) classifications? Building on Tupper’s 
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(2012) work, Duff argued that ‘cannabis’ can no longer be regarded as a 
singular entity at all, “… given the diversity of relations, practices, semiotic 
registers and political squabbles in which the drug is produced as an object of 
knowledge and practice” (2017: 677). Duff (2017) also argued, using two of 
Tupper’s (2012) three categories, that ‘cannabis’ may be changing from a 
‘drug’ to a ‘non-drug’. Elements of articulating cannabis as a ‘non-drug’ and 
opposing it to other ‘drugs’, and sometimes ‘non-drugs’ like alcohol, are found 
in the excerpts discussed by myself below.         
 
Method and methodology 
Thirty-three disabled and/or chronically ill people were recruited by way of 
advertising and the use of a ‘snowball’ sampling technique (Becker 1963). Of 
the 32 participants whose data was used (one interview could not be 
transcribed), 13 were male and 19 were female. The study group also covered 
a broad range of forms of chronic illness (some of which may or may not lead 
to impairment) and types of impairment. The most common forms of chronic 
illness were multiple sclerosis (14 participants) and various forms of arthritis 
(eight). Other chronic illnesses and/or forms of impairment that participants 
had included chronic fatigue syndrome, respiratory and muscle weakness, 
orthopaedic problems, congenital fibromyalgia, spondylitis, cerebellar ataxia 
and spinal chord injuries. Of the 32 participants, two were aged below 30, 
eight were aged between 30 and 40, 14 were aged between 40 and 50, six 
were aged between 50 and 60 and two were aged over 60, the mean age of 
participants being 44.5 years of age. Participants primarily reported using 
cannabis medicinally due to dissatisfaction with prescribed medication. 
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Semi-structured interviews were conducted with all participants. In all but two 
instances, these were done at their homes (the other two elected to come to 
my university office). The length of the interviews varied from approximately 
ninety to one hundred and eighty minutes. Ethical approval for both the 
original research and thesis were obtained from the XXXX for peer review 
Research Ethics Committee. It was decided not to use a complex transcription 
system, such as the Jefferson transcription system, as most of the detail that 
this provides was not required and it would have hindered ease of readability. 
A critical discourse analysis approach to the data was employed. Of the 33 
participants interviewed, the data from 32 was used in the study reported on 
here. One of the participants had a severe speech impairment that, 
unfortunately, made transcribing that interview too difficult. A paper-based 
approach to analysis was preferred to computer-aided analysis, allowing me 
to get closer to the data. The initial stage of analysis involved reading and re-
reading transcripts and revisiting interview recordings, to familiarise myself 
with the data. Following this, coding took place. What is presented here is just 
one part of the analysis, reflecting on the accounts of ten participants whose 
articulations are illustrative of the 19 that articulated cannabis as being 
‘natural’. 
 
In terms of demographic characteristics, the 10 participants (made 










Catherine 46 Arthritis Clerical work Compulsory 
Charles 41 Multiple sclerosis Army officer Compulsory 
Danny 59 Spondylitis Labourer Art College 
Ruth 45 Rheumatoid arthritis Social worker Graduate 
Simon 39 Poly arthritic Car mechanic Compulsory 
Wendy 32 Fibromyalgia Disability 
assistant 
Graduate 
Grace 41 Rheumatoid arthritis Head of policy Post-grad. 
Keith 28 Cerebellar Ataxia Clerical work Compulsory 
Felicity 43 Multiple sclerosis TV producer Post-grad. 
Deborah 56 Multiple sclerosis Bank clerk Compulsory 
Table 1 Summary of participant information. 
Whilst this article is concerned with discourse analysis and how the 
participants rhetorically negotiated stigma in the interviews, readers may care 
to know a little more about the cannabis use practices of those discussed. In 
terms of administration, seven of the ten participants discussed smoked 
cannabis, two mainly ate and drank it and one smoked, ate and drank it. This 
is in keeping with the overall sample of 32, 24 of whom smoked it. Ten of the 
24 that smoked cannabis had health concerns about doing so, but 
acknowledged that they found it the most effective way to use it (in terms of 
gauging an effective dose). Reported reasons for use all related to symptom 
management. The stated perceived benefits were most commonly pain 
management, then bodily relaxation (addressing stiffness and spasms in 
some cases), enhanced sleep and addressing mood/depression. Again, pain 
management was the most common response within the overall sample of 32 
participants, with a range of other symptom-related benefits also discussed. 
When asked whether they needed to feel a ‘high’ to achieve the required 
symptom management, eight of the ten discussed in this paper replied ‘no’. 
Danny and Keith replied yes, stating that this helped them with low mood. Out 
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of the overall 32, seven participants sought a ‘high’, again to enhance low 
mood.   
 
Articulations from the medicinal cannabis users’ discourses 
 
(i) Articulations of ‘nature’ and the ‘natural’ 
It became apparent, relatively early in the interviewing period, that talking 
about ‘nature’ and the ‘natural’ were of considerable significance and 
occupied a central role in the discourses of the majority of participants I 
interviewed. Whilst I only discuss the articulations of 10 participants in this 
paper (due to space), 19 of the total of 32 participants discussed cannabis in 
relation to ideas about ‘nature’ and the ‘natural’. Those who shared the 
common sense assumption that ‘natural’ is intrinsically healthier frequently 
articulated this when discussing their use of cannabis. Rhetorically, this has 
the effect of downplaying the potential for the application of stigma in the 
ongoing negotiation during the interviews of how cannabis is signified and, 
thereby, how they as individuals are potentially categorised (Hammersley et 
al., 2001) by the interviewer. Sometimes, this was articulated in short 
comments, for example: 
 
Catherine: I still think it’s [cannabis] healthier. I really do. More 
natural, you know.  
 
This brief comment from Catherine draws on the prevalence and taken-for-
grantedness of the notion that ‘natural is better’ (Coward 1989; cited in Lypton 
1995). If an idea has come to attain the status of being ‘common sense’ it 
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tends to be understood as requiring little or no qualification, as we see here 
from Catherine. In terms of conversations often involving the imposition of one 
understanding of an issue over another, this is very powerful, rhetorically. 
Considering the participants’ interviews in the context of the UK government’s 
and medical authorities’ refusal to see cannabis as medicinally useful (BMA, 
1997), (which has only in 2018 changed, and then only regarding cannabis-
based medicine, not cannabis itself) this is significant. Powerful and accepted 
discourses must be drawn on to contest other powerful discourses.  
 
Charles, unlike Catherine (and unlike Danny below), makes rhetorical effort to 
emphasise his own responsibility (Hathaway et al., 2011) in his negotiation of 
the signification (Hammersley et al., 2001) of cannabis and, thereby, the 
categorisation of himself as a responsible person. Again, articulating ideas 
about cannabis as being ‘natural’ has the effect of downplaying the potential 
for the application of a deviant identity within the interview: 
 
Charles: … I use something that’s entirely natural [cannabis], 
that can’t be too bad. I don’t see that there’s a problem in that, in 
that there is, I don’t know, shall we, shall we say that it was 
going to be beneficial for you as a human being to have two 
glasses of mineral water a day, chances are that you’d have two 
glasses of mineral water a day and I believe, I don’t see what’s 
wrong with it, I mean, as an entirely natural substance 
[cannabis] … . 
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As before (with Catherine), Charles employed the power of articulating a 
‘common sense’ argument. This time, the widely accepted health benefits of 
drinking mineral water, which itself draws on the power of ‘natural is better’ 
(Coward 1989; cited in Lypton 1995), is brought into play. Interestingly, from a 
rhetorical perspective, this quote begins and ends with the phrase “entirely 
natural”. This is an example of extreme case formulation (Jefferson, 1991, 
cited in Woofitt, 1993). Inter-textually, notions of purity are being brought into 
play and emphasised further by the term ‘entirely’, so this fairly brief passage 
of articulation draws on the power of the ‘common sense’, the likening to 
another practice that is commonly accepted as being healthy and this excerpt 
begins and ends by articulating notions of purity. 
 
Some interviews featured narratives that located cannabis in relation to what 
can be seen as the fragile trust in science, medicine, technology, government 
and ‘expertise’ (Beck 1992) and the related, and equally fraught, public 
discourse on the relationship between society and nature (Beck 1992; Nerlich 
et al. 1999; Sutton 1999). The following excerpt features such ideas, by 
articulating the idea of nature as a system of cures: 
 
Danny: …it is as if God gave me it [cannabis] in, it’s part of 
creation. But as in many things you’ll find that, for many 
conditions there are natural cures that exist in nature, you know.  
[…] but it seems that because of vested interest, man has, has 
purified certain chemicals and taken bits out and, and use those 
instead of using the whole of it [cannabis] and the ones, and 
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there seems to be a vested interest in, in keeping people using 
patented medicines instead of using natural cures … . 
 
This excerpt contrasts the assumed inherent goodness of nature and God 
with the vested interests of humanity – the implied, but unnamed, 
pharmaceutical companies. In a good versus evil type narrative, the plea to 
have cannabis seen as something righteous is, again, rhetorically powerful as 
an attempt to downplay the potential for the application of deviance during the 
interview. 
 
(ii) Cannabis opposed to chemical substances 
Six participants, of whom I will discuss three (due to space), spoke about 
cannabis by opposing it to ideas about ‘chemical’ substances in various ways. 
Participants’ articulations of cannabis’ ‘natural’ qualities often involved the use 
of the rhetorical strategy of contrasting it with other substances (prescribed 
medicines, other illicit drugs, tobacco and alcohol), with these being 
articulated in ways that emphasised connotations that are increasingly 
associated with manufactured risk (Giddens, 1999). Such articulations use 
both downplaying and shifting strategies. 
 
Annie gave an interesting account that hints at where her ideas came from.  
 
Annie: I have very good friends that looked after me and they 
educated me with it. They, they’ve forbidden me to take any 
amphetamines, like what they used to be called then, speed, 
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acid, mushrooms, coke, heroin. They forbidded (sic) it. They 
forbidded any chemicals… . 
 
Annie: …all the tablets that doctors give you, why the hell can’t 
they do it to the cannabis, because the chemicals the doctors in 
the pharmacy give you do more damage… . 
 
The “very good friends” to whom she referred were a group of bikers that she 
was a part of. In the first excerpt, Annie lists substances she was forbidden to 
take. Forbidden is quite a strong word and it emphasises the risks inherent in 
their consumption if they are “forbidden” things (the possible contradiction of 
including mushrooms in a list of non-naturally occurring substances is 
overlooked). The second excerpt suggests an interpretation made by Annie, 
or at least constructed within this account, of the iatrogenic effects (Illich, 
1995) of her encounters with the medical profession being due to the 
“chemical” constituency of prescribed medicines that she had been given. In 
both excerpts, shifting is used, with the risks of consuming “chemical” 
substances being alluded to.  
 
Another participant, Deborah, constructs cannabis in opposition to the 
‘chemical’ in a more direct and explicit excerpt. 
 
Deborah: Yes I have Diazepam for spasm. For me, in an ideal 
world, I would go for physiotherapy, no drugs like that, they’ve all 
got side-effects and some cannabis, which I think is more 
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natural somehow a more natural substance. I may be totally 
wrong. I know it’s natural because it grows as opposed to some 
sort of chemical thing… . 
 
In this excerpt, prescribed substances, like Diazepam, were constructed as 
having side-effects and cannabis was constructed as not having side-effects, 
or at least less likely to because it is ‘natural.’ The risks of using cannabis are 
downplayed and the risks of using “some sort of chemical thing” are 
emphasised, partly using extreme case formulation (Jefferson, 1991, cited in 
Wooffitt, 1993) in “they’ve all got side-effects”.  The absolute certainty of her 
ontological category of ‘natural’ is questioned for a brief moment but then 
reaffirmed by the common-sense assertion that it must be natural “because it 
grows.”  
 
Ruth articulated cannabis by way of a discursive opposition, as being natural 
and therefore preferable to non-natural prescribed medicines, which are not. 
 
Ruth: I regarded it [cannabis] more as a natural product, rather 
than things like Valium and alcohol and the other types of drugs 
that were about. I’ve never really looked upon it as being in the 
same context as things like Valium, right, which help to relax 
you. I’ve always regarded Valium as a pharmaceutical type drug 
which I don’t have any time for.  
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Here, the distinction between cannabis, as a ‘natural’ substance, and Valium 
and “the other types of drugs that were about”, as dangerous manufactured 
drugs, is constructed. Rhetorically, both downplaying and shifting are evident, 
as Ruth downplays the risks of cannabis use by articulating it as a “natural 
product” and then describes Valium as a “pharmaceutical type drug”. An 
opposition is constructed, in which all manner of risk connotations associated 
with manufactured risk are connoted. 
 
(iii)  Articulations of cannabis and what is/is not a ‘drug’ 
The argument that cannabis is not a ‘drug’ is an interesting discursive 
assertion and one that both Tupper (2012) and Duff (2017) address (a ‘non-
drug’ in their terms). Articulating cannabis as a non-drug has the rhetorical 
advantage for participants of downplaying the perception of cannabis as 
risky/problematic and reducing the possibility of the participant being 
stigmatised in the negotiation of their identity during the interview. It draws on 
the previously discussed ideas that cannabis is safe and benign and opposes 
this to the ideas of ‘drugs’ as substances that are dangerous in numerous 
ways, thus shifting the potential for stigma onto them. The notion that 
cannabis is a ‘soft’ drug draws explicitly on the ‘soft’ drug/‘hard’ drug 
discursive dichotomy that has great prevalence in the discussion of drugs in 
everyday life (Coomber, 2000). In this respect it might be argued that such 
articulations draw on culturally prevalent ways of talking about and 
understanding drugs (Glassner and Loughlin n.d., cited in Silverman, 1994), 
which can be taken as reflecting and articulating the ‘normalisation’ among 
some in society of certain drugs, particularly cannabis, in recent years (Parker 
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et al., 1998), which in the practical understandings of many has detached 
cannabis from connotations of ‘risk’ and ‘abnormality’. This detachment tends 
to be partial though. If it were not, we would not see as much rhetorical 
negotiation around drug user identities and the signification of the drugs they 
consume. Hathaway et al.’s (2011) discussion is relevant here, as my 
participants clearly have either internalised stigma or, at the very least, are 
aware of the possibility of it being applied to them. These articulations of 
cannabis ‘not being a drug’ are not limited to the U.K., as can be seen in 
Omel’chenko’s (2006) discourse analysis of Russian drug users sometimes 
constructing cannabis as ne narkotik (not drugs).  
 
The argument that cannabis is not really a drug was explicitly made by three 
participants and employs an opposition being articulated between cannabis 
and other illicit substances (typically the so-called ‘hard’ drugs of ‘crack’ 
cocaine and heroin), often drawing on the discursive distinction between the 
‘natural’ and the ‘chemical’. However, this dichotomy is incredibly prevalent in 
the accounts of participants in relation to all kinds of issues. The discursive 
category of the ‘natural’ is taken by most participants to be intrinsically 
preferable in many ways but particularly in terms of safety. ‘Chemical’ 
substances are typically constructed as dangerous.  
 
Simon: People just don’t know anything about it, do they? 
They don’t, they don’t see that cannabis is not really a 
drug, is it? It’s something totally different. It’s away from all 
the chemicals like heroin and cocaine, the ‘crack’… . 
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Wendy: So any chemical drugs, I’m opposed to probably 
nearly all of them and it’s, it’s a different category. I, in my 
mind, I don’t perceive cannabis as a drug per se. I see it as 
a remedy or a relaxant or whatever and I would never 
touch things like heroin, ’crack’… . 
 
Both Simon and Wendy downplay stigma by insisting that cannabis is 
not a ‘drug’ and they shift the potential for categorisation (Hammersley et 
al., 2001) of themselves as deviant by opposing cannabis to other 
‘drugs’. Simon and Wendy reinforce the distinction by speaking about 
what are arguably the two most stigmatised drugs in the UK, heroin and 
‘crack’. The associations that these drugs carry in the minds of many, 
those of addiction, criminality and generally a high level of risk, greatly 
adds to the distance that these two participants are constructing 
between themselves and users of these other substances. 
  
Grace explicitly articulated cannabis as a ‘soft’ drug in her interview, very 
simply downplaying the risks of cannabis use and shifting potential stigma 
onto users of ‘hard’ drugs. In doing so, she made use of the prevalence of the 




Grace: I considered it [cannabis] a soft drug. I would never 
take hard drugs and I’ve also got complete phobia about 
needles … .   
 
Keith problematised the broad term ‘drugs’ and argued that the term tends to 
homogenise the different substances that it encompasses. He used the 
examples of cannabis and heroin and also argued that alcohol and cigarettes 
are “far worse” than cannabis (shifting) and that if cannabis is to be included 
in this all encompassing term ‘drugs’ then so should they. 
 
Keith: I think one of the problems as well is that they, they, because 
it’s unfortunate but, because drugs is such a broad term, you know? 
People say drugs, yeah, and they include cannabis in the same 
word that seems like heroin. They’re just not the same, you know? If 
you’re going to do that then you might as well mention alcohol and 
cigarettes, you know, things that are far worse. 
 
Another participant, Terry, can also be seen as questioning the language 
used in terms of what is seen as a drug and what is not, around alcohol. 
 
Terry: I kept it [smoking cannabis] a secret for a while 
because they’ve [his parents] made it plain that they were 
anti-drugs, anti-drug use completely, apart from the fact 
that they used to drink wine quite regularly, which to me is 
drug use.  
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Earlier in this section a number of participants were shown arguing that 
cannabis is not a ‘drug’, whereas Keith and Terry argued that other 
substances not usually spoken about as being ‘drugs’, cigarettes and alcohol, 
are ‘drugs’. This is significant when one of the main tenets of discourse 
analysis is considered, i.e. that discursive constructions shift subject to what 
individuals are using language to accomplish. Bearing this in mind, 
participants often either argued that cannabis was not a ‘drug’ or that other 
substances were ‘drugs’, with the effect usually being to downplay the stigma 
of cannabis or to shift the application of stigma onto other substances and 
their users.  
 
Cannabis as ‘natural’: The power of prevalent common-sense discourse 
In this paper, I have presented and reflected upon articulations of three inter-
related themes and how these were used to downplay stigma, shift stigma or 
both. The three inter-related themes were ideas about cannabis being a 
‘natural’ substance, rhetorical constructions of cannabis in opposition to ideas 
about ‘chemical’ substances and discursive constructions of what is/is not a 
‘drug’. In practice, there is a degree of overlap between these. For example, 
cannabis may be articulated as safe and, therefore, the user as ‘not’ being 
deviant because it is ‘natural’, not ‘chemical’, with the assumed risks of such 
substances and an example of a ‘chemical’ ‘drug’, such as Valium, may have 
its’ risks emphasized to, in turn, downplay the dangers of using cannabis.  
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Much of the rhetorical work focused on here involved the idea, assumed to be 
self-evident by the participants, that ‘natural is best’. As negotiations of the 
signification of cannabis within the interview, and thereby of the potential 
categorization of themselves as deviant or otherwise (Hammersley et al., 
2001), this is effective and draws on highly prevalent discourses in everyday 
life about natural products and lifestyles as being preferable (Moscato and 
Machin, 2018; Rozin et al., 2004; Nissen, 2015). The articulations involving 
ideas about cannabis, ‘nature’ and the ‘natural’ downplay the deviance of 
cannabis use very effectively. How can it be wrong, it’s natural?! The shifting 
articulations opposed cannabis to other, ‘chemical’, substances and those that 
negotiate around whether cannabis is a ‘drug’ or whether it is other 
substances that are ‘drugs’, also depend on ideas about nature being 
preferable to that which is ‘chemical’. Why is this idea so central to these 
articulations? 
 
Whilst these articulations were specific to the situation in which they were 
produced (my interviews with the participants), they drew on existing ideas. 
These ideas can collectively be conceptualised as part of a heterodoxical 
discourse, one that arises to challenge dominant beliefs (Bourdieu, 1979; 
1992). Bourdieu argued that to be successful in challenging dominant beliefs, 
heterodoxical discourse has to produce a new common sense. The core 
articulations of cannabis as ‘natural’ achieve this rhetorical function and draw 




 “ ...  safe, gentle and [having] inherent properties which will 
benefit individuals” (Coward 1989: 19; quoted in Lypton 1995).  
 
Articulations of ‘nature’, the ‘natural’ and cannabis hold this heterodoxical 
potential due to the sheer discursive prevalence of ‘nature’ and ‘the natural’ 
tending to be understood as inherently preferable in a range of ways to 
‘chemical’ products. Further, the prevalence of this thinking is increasing in 
day-to-day public discourse in relation to numerous issues (see Moscato and 
Machin, 2018; Nissen, 2015; Rozin et al., 2004) and holds significant potential 
if drawn on.  
 
I say if drawn on, because discursive resources do not articulate themselves. 
We have seen excerpts from participants that are challenging, critical, and 
questioning in their constitution. Where do these participants get their power 
to do this? In a discussion of Bourdieu’s work, Deer (2008) points out that 
heterodoxy most efficiently arises from those social groups who are relatively 
high in cultural capital but relatively low in economic capital (they have plenty 
to use in their arguments and plenty to argue about). Many of the participants 
discussed in this paper do fit into this social class fraction: Ruth the social 
worker, Grace the Head of Policy, Felicity the TV producer, even Danny the 
labourer who had been to art college and romantically professed to prefer the 
honesty of manual labour. However, some do not fit this high in cultural 
capital but low in economic capital class position, such as Simon the 
mechanic, Deborah the bank clerk and Keith the clerical worker (all with 
compulsory levels of education). To explain their articulation of this 
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heterodoxical discourse I will only argue that the sheer prevalence of ideas 
about ‘natural being better’ and fears about the risks of ‘chemical’ substances 
mean that they are within the reach of most members of society, especially in 
the age of the internet, not just those higher in cultural capital. 
 
Deer also says that “… though it may seek to be critical and even heretic, 
heterodoxy often remains mediated by the ruling doxa” (2008: 124). Not that I 
would see it as doxa, due to a high level of disputation, but ideas about 
cannabis being a ‘drug’, a psychoactive substance associated with various 
types of danger and risk and a moral stigma attached to its’ use still exist, at 
least for many (see Author, 2018). It may also be the case that the multiplicity 
of cannabis products, particularly those that are medicinally-oriented, will 
increasingly challenge this (see Duff, 2017). For now though, I think these 
ideas do “mediate” the heterodoxical articulations discussed in this paper to 
some degree. To revisit Hathaway et al.’s (2011: 451) discussion of 
Goffman’s distinction between normalization and normification:  
 
“ … stigma is internalized by users which results in the active 
reinforcement and performance of established cultural requirements 
emphasizing self-control.” 
 
Whilst my participants articulate a heterodoxical discourse in which cannabis 
is ‘natural’, safer than other ‘drugs’ and medicines, a non-drug and so on, they 
do seem to have internalized the stigma, or at least to be aware of the 
potential of having it applied to them, and often argue hard against it and the 
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possibility of being categorised (Hammersley et al., 2001) as ‘drug’ users, with 
the various negative connotations that holds for them.  
 
As regards emphasizing self-control, there are two points to make. The 
articulations in relation to what is/is not a ‘drug’ and oppositions with 
‘chemical’ substances tended to feature these emphases more explicitly and 
with more rhetorical work being done by the participants. Compare these to 
the articulations around cannabis being a ‘natural’ substance, which tended to 
involve less discursive effort. My view is that the ability of discourses, about 
‘natural being better’, to pass as common sense means that articulators of 
these discourses may feel that they need to argue less hard to be convincing 
when using them. They may feel that self-control is demonstrated simply 
because ‘natural’ is self-evidently, at least to them, safe and beneficial. 
Secondly though, in articulating in ways that construct cannabis as ‘natural’, in 
opposition to ‘chemical’ substances (and emphasizing the risks of these) and 
articulating cannabis as not a ‘drug’, the participants are consistently 
emphasizing their individual self-control. In terms of Hammersley et al.’s 
(2001) ideas about negotiation and categorisation, individual self-control is 
something the participants clearly sought to emphasize when talking about 
their cannabis using practices and, in doing so, themselves.  
  
Conclusion 
As is commonly found in the articulations of substance users, medicinal 
cannabis users employed various rhetorical strategies to negotiate their own 
positive moral standing. My participants’ discourses placed great importance 
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on the idea that ‘natural is best’. I have argued that such discourses may be 
seen as effective because they draw on the powerful heterodoxical meta-
discourse about ‘nature’ that is highly prevalent in many aspects of everyday 
life. My participants also articulated ideas that involved constructing discursive 
oppositions between cannabis and other substances and articulating ideas 
about whether cannabis is actually a ‘drug’ or not. Articulation of all three 
themes involved using rhetorical strategies I have referred to as downplaying 
and shifting.   
 
Of the three themes discussed in this paper, I have argued that participants 
had to engage in more rhetorical work when articulating oppositions between 
cannabis and others substances and whether cannabis was or was not a 
‘drug’, than when discussing cannabis as a ‘natural’ substance. The 
implication of this is that the more powerful the discursive resources being 
articulated, the less rhetorical work an individual has to do to negotiate 
positive moral standing in an encounter when drawing on them. An interesting 
question arising from this is at what point does a heterodoxical discourse 
have enough force behind it so that it has taken on the status of being a new 
common sense? 
 
Finally, I was also interested in Hathaway et al.’s (2011) discussion of the 
internalization of stigma and the need to emphasise self-control when 
discussing substance use. Whether my participants had internalized stigma or 
were simply aware of the potential of it being applied to them is an interesting 
question, but the struggle to achieve and maintain an identity that refuted the 
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application of stigma is what elicited the articulations discussed in my paper. 
Individual self-control is something the participants clearly sought to 
emphasize when talking about their cannabis using practices and, in doing so, 
talking about themselves. Even medicinal cannabis users, with the sympathy 
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